In this report the features of lymph node involvement and biclonality constitute a rare presentation of multiple myeloma.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Multiple myeloma is characterized by plasma cell infiltration of the bone marrow and the presence of a monoclonal protein in the plasma or the urine in 90% of cases.
📊
Key Findings & Data:Less frequent presentations are hepatic and splenic enlargement (5% of cases), lymphadenopathy (4%) and biclonal gammopathy (1%).
💡
Conclusion & Impact:In this report the features of lymph node involvement and biclonality constitute a rare presentation of multiple myeloma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İmmünohistokimya · Yaşlı · Multipl miyelom
Özet
Multiple myeloma is characterized by plasma cell infiltration of the bone marrow and the presence of a monoclonal protein in the plasma or the urine in 90% of cases. Major manifestations of the disease are bone pain, anemia, renal insufficiency and recurrent infections. Less frequent presentations are hepatic and splenic enlargement (5% of cases), lymphadenopathy (4%) and biclonal gammopathy (1%). In this report we describe a biclonal multiple myeloma presenting with cervical lymphadenopathy and sternal mass. The immunohistochemical study of the lymph node and the flow cytometric analysis of the bone marrow showed IgGK and IgAK biclonality. In this report the features of lymph node involvement and biclonality constitute a rare presentation of multiple myeloma.
Österborg A, Hansson LO, Mellstedt H. Immunoglobulins in multiple myeloma. In: Gahrton G, Durie B (eds). Multiple Myeloma. 1st ed. London: Oxford University Press, 1996:36-50
Di Stasi M, Cavanna L, Paties C, Fornari F, Civardi G, Binelli F, Buscarini E, Buscarini L. Anaplastic myeloma as extramedullary relapse of multiple myeloma in remission. Acta Haematol 1986;76:202-7
Zervas K, Constantinou N, Karakantza M, Tsigalidou-Balla V. Anaplastic myeloma. Leuk Lymphoma 1995;16:515-8
Österborg A, Mellstedt H. Monoclonal and biclonal immunoglobulin-producing disorders. Eur J 1989;43(Suppl 51):11-8
Kyle RA, Robinson R, Katzman J. The clinical aspects of biclonal gammopathies. Am J Med 1981;71:999-1006
Kyle RA. Multiple myeloma: A review of 869 cases. Mayo Clin Proc 1975;50:29-40
Goranov S. Clinical aspects of biclonal myelomas. Folia Med 1994;36:31-6
Pizzolato M, Bragantini G, Bresciani P, Pavlovsky S, Chuba J, Vidal R, Rostagno A, Ghiso J. IgG1-k biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism. Br J Haematol 1998;102:503-8
Bast EJEG, Slaper-Cortenbach CM, Verdonck LF, Samson W, Ballieux RE. Transient expression of a second monoclonal component in two forms of biclonal gammopathy. Br J Haematol 1985;60:91-7
Goni F, Chuba J, Buxbaum J, Frangione B. A double monoclonal IgG1k and IgG2k in a single myeloma patient. Variation in clonal products and therapeutic responses. J Immunol 1998;140:551-7
Daeninck PJ, Williams G, Rubinger M, Johnston J. Multiple myeloma presenting clinically as lymphoma. Leuk Lymphoma 1997;28:195-201
Strand W, Banks P, Kyle R. Anaplastic plasma cell myeloma and immunoblastic lymphoma. Am J Med 1984;76:861-6.